AR-V7 as a Biomarker for Resistance to Treatment with Abiraterone/Enzalutamide in Three Latin American Countries: A Hypothetical Cost-Saving Analysis

Abstract

Background. Prostate cancer is the most incident and one of the deadliest male cancers in Latin America. Treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) includes androgen receptor signaling inhibitors such as abiraterone and enzalutamide, for which androgen receptor splice variant 7 (AR-V7) has emerged as a biomarker for primary resistance. Our study sought to analyze the potential economic impact of the use of AR-V7 detection as a treatment indicator in patients with mCRPC in three Latin American countries. Materials and Methods. A hypothetical cost prediction model for the use of noninvasive circulating tumor cellbased AR-V7 testing as a treatment indicator for patients eligible for treatment with abiraterone/enzalutamide was conducted using available information on treatment and testing costs from Mexico, Argentina, and Colombia.

Correlation between E‐cadherin/β‐catenin, Vimentin expression, clinicopathologic features and drug resistance prediction in naïve prostate cancer: A molecular and clinical study

“…Abi in combination with prednisone, a first-generation androgen biosynthesis inhibitor, has recently been shown to improve the survival of patients with advanced PC by inhibiting the production of glucocorticoids, which are required for testosterone production (Beer et al, 2014;Ryan et al, 2013;Scher et al, 2012). However, the majority of patients develop resistance to ADT over time through androgen receptor (AR) variants and androgen biogenesis, including Cytochrome P450 17A1 (CYP17) (Pacheco-Orozco et al, 2020). Following this resistance, cancer progression in PC patients is typically managed with taxanes, the only line of chemotherapy using Paclitaxel ® , Docetaxel ® , and Cabazitaxel ® as drugs to extend the lives of men affected by PC.…”